Stephen Burley named leader of cancer pharmacology research at Rutgers Cancer Institute of New Jersey

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

STEPHEN BURLEY was named as co-program leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey.

Burley will work with co-program leader X.F. Steven Zheng, a university professor at Rutgers Robert Wood Johnson Medical School, in determining the mode of action and mechanism of resistance to anti-cancer agents and developing novel concepts and strategies for cancer treatment.

Burley has been a full research member of Rutgers Cancer Institute since 2013. He is the director of the Center for Integrative Proteomics Research, founding director of the Institute for Quantitative Biomedicine, and a distinguished professor of chemistry and chemical biology in the School of Arts and Sciences at Rutgers University. He also serves as director of the Research Collaboratory Structural Bioinformatics Protein Data Bank.

YOU MAY BE INTERESTED IN

“Backwater to Blockbuster,” the first de novo book published by the Cancer History Project, traces the evolution of St. Jude Children’s Research Hospital to its current status of a powerhouse of research in pediatric cancer.

The U.S. Department of Justice issued a letter alleging that Yale Medical School of violating anti-discrimination laws and instititing policies that disadvantaged white and Asian applicants while favoring Black and Hispanic applicants.  The DOJ investigation, which was launched a year ago, reviewed the school’s admission policies for the class of 2023, 2024, and 2025, the...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login